Watchdog Dodges Legal Bills In £89M Drug Cos. Case

Law360, London (May 12, 2020, 2:55 PM BST) -- An appellate court ruled on Tuesday that the antitrust watchdog does not have to pay Pfizer and another drug company legal fees it spent defending an £89.4 million ($110 million) case over medication prices, saying the regulator was carrying out its duties. 

The Court of Appeal has overturned a decision by a specialist tribunal that forced the Competition and Markets Authority to cover the cost of proceedings over a decision by Pfizer and Flynn Pharma to raise prices on an anti-epilepsy drug.

The CMA fined Pfizer and Flynn for breaching antitrust rules, but was forced to reconsider after the Competition Appeal...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!